Evidence map›Paper›PMID 40295472›Full record

ArticleBlood cancer journal2025

Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis.

Cecilie Velsoe Maeng, Sæmundur Rögnvaldsson, Thórir Einarsson Long, Christian Brieghel, Emil Hermansen, Carsten Utoft Niemann, Kirsten Grønbæk, Sigurður Yngvi Kristinsson, Sigrún Thorsteinsdóttir

Erratum issuedAbstract read
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Cecilie Velsoe MaengDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. cecilie.velsoe.maeng@regionh.dk.ORCID http://orcid.org/0000-0002-7205-9330
Sæmundur RögnvaldssonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.
Thórir Einarsson LongFaculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID http://orcid.org/0000-0003-2377-7886
Christian BrieghelDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-1816-8106
Emil HermansenDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-1754-5336
Carsten Utoft NiemannDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-9880-5242
Kirsten GrønbækDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Sigurður Yngvi KristinssonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID http://orcid.org/0000-0002-4964-7476
Sigrún ThorsteinsdóttirDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-5017-3530

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The free light chain (FLC) ratio is a critical part of risk stratification for monoclonal gammopathy of undetermined significance (MGUS). Recently, revised FLC reference intervals developed using the iStopMM cohort, accounting for age and renal function, have reduced the rate of abnormal findings. Here, we examine the implications of the revision in an independent Danish MGUS cohort. Of 6993 MGUS individuals, 2641 had an abnormal FLC ratio by the original intervals, of whom 844 (32%) were reclassified as normal using the revised intervals. Reclassified individuals had no significantly increased risk of progression compared to those with a normal FLC ratio (hazard ratio (HR): 1.07, 95% confidence interval (CI) 0.74-1.57). Those with an abnormal FLC ratio by the revised reference intervals had an increased risk of progression (HR 2.23, 95% CI 1.79-2.78). Using the revised reference intervals, 490 individuals (16%) were reclassified to low-risk from a higher risk group. These individuals had a similar progression risk compared to others in the low-risk group. The findings validate the revised FLC reference intervals, enhancing prognostic accuracy and improving risk stratification to accurately identify MGUS individuals at risk of progression while reducing unnecessary classifications as high-risk.

Indexed as

Immunoglobulin Light ChainsMedical OveruseMonoclonal Gammopathy of Undetermined SignificanceAdultAgedAged, 80 and overDenmarkDisease ProgressionFemaleHumansMaleMiddle AgedReference ValuesRisk AssessmentImmunoglobulin Light Chains

Identifiers

PMID40295472
PMCPMC12037766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.